Insider · CIK 0001620014

Exter Neil

Reports to the SEC for 6 companies · SOUTH SAN FRANCISCO, CA

sec.gov

Transactions

Companies

Filings

CIK

0001620014

Forms 4 and 5

Insider transactions

41 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2025-09-22	MAZEMaze Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+18K sh	—	—	18,000
2025-08-17	MAZEMaze Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+16K sh	—	—	16,000
2022-06-17	Decibel Therapeutics, Inc.Stock Option (right to buy)A Award	Director, 10% Owner	AAward	+10K sh	—	—	10,000
2022-06-16	PLRXPLIANT THERAPEUTICS, INC. · Stock Option (right to buy)A Award	Director	AAward	+15K sh	—	—	15,000
2022-06-16	RVMDRevolution Medicines, Inc.A Award	Director	AAward	+5,200 sh	—	—	28,815
2022-06-16	RVMDRevolution Medicines, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+18.4K sh	—	—	18,400
2022-06-08	RVMDRevolution Medicines, Inc.S Sale	Director	SSale	0 sh	—	—	0
2021-06-29	PLRXPLIANT THERAPEUTICS, INC. · Stock Option (right to buy)A Award	Director	AAward	+13.3K sh	—	—	13,286
2021-06-22	RVMDRevolution Medicines, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+12.7K sh	—	—	12,659
2021-06-22	RVMDRevolution Medicines, Inc.A Award	Director	AAward	+3,617 sh	—	—	23,615
2021-06-04	RVMDRevolution Medicines, Inc.S Sale	Director	SSale	0 sh	—	—	0
2021-06-03	RVMDRevolution Medicines, Inc.S Sale	Director	SSale	0 sh	—	—	0
2021-05-26	RVMDRevolution Medicines, Inc.S Sale	Director	SSale	0 sh	—	—	0
2021-05-25	RVMDRevolution Medicines, Inc.S Sale	Director	SSale	0 sh	—	—	0
2021-02-24	RVMDRevolution Medicines, Inc.J Other	Director	JOther	0 sh	—	—	0
2021-02-17	Decibel Therapeutics, Inc.Series A Preferred StockC Conversion	Director, 10% Owner	CConversion	−45.6M sh	—	—	0
2021-02-17	Decibel Therapeutics, Inc.Series D Preferred StockC Conversion	Director, 10% Owner	CConversion	−290K sh	—	—	0
2021-02-17	Decibel Therapeutics, Inc.Series C Preferred StockC Conversion	Director, 10% Owner	CConversion	−1.25M sh	—	—	0
2021-02-17	Decibel Therapeutics, Inc.C Conversion	Director, 10% Owner	CConversion	+54.6K sh	—	—	3,139,685
2021-02-17	Decibel Therapeutics, Inc.C Conversion	Director, 10% Owner	CConversion	+98.9K sh	—	—	3,085,043
2021-02-17	Decibel Therapeutics, Inc.C Conversion	Director, 10% Owner	CConversion	+2.94M sh	—	—	2,986,114
2021-02-11	Decibel Therapeutics, Inc.Stock Option(right to buy)A Award	Director, 10% Owner	AAward	+20K sh	—	—	20,000
2020-12-02	RVMDRevolution Medicines, Inc.J Other	Director	JOther	0 sh	—	—	0
2020-09-09	RVMDRevolution Medicines, Inc.J Other	Director	JOther	0 sh	—	—	0
2020-06-05	PLRXPLIANT THERAPEUTICS, INC.C Conversion	Director	CConversion	0 sh	—	—	0
2020-06-05	PLRXPLIANT THERAPEUTICS, INC. · Series A Preferred StockC Conversion	Director	CConversion	0 sh	—	—	0
2020-03-31	PLRXPLIANT THERAPEUTICS, INC. · Stock Option (right to buy)A Award	Director	AAward	+26.6K sh	—	—	26,573
2020-02-18	RVMDRevolution Medicines, Inc. · Series B Convertible Preferred StockC Conversion	Director	CConversion	0 sh	—	—	0
2020-02-18	RVMDRevolution Medicines, Inc.C Conversion	Director	CConversion	0 sh	—	—	0
2020-02-18	RVMDRevolution Medicines, Inc. · Series A Convertible Preferred StockC Conversion	Director	CConversion	0 sh	—	—	0
2020-02-18	RVMDRevolution Medicines, Inc. · Series C Convertible Preferred StockC Conversion	Director	CConversion	0 sh	—	—	0
2020-02-12	RVMDRevolution Medicines, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+36.2K sh	—	—	36,168
2018-06-06	RYTMRHYTHM PHARMACEUTICALS, INC. · Stock Option (right to buy)A Award	Director	AAward	+10K sh	—	—	10,000
2017-10-10	RYTMRHYTHM PHARMACEUTICALS, INC. · Series A-1 Junior Preferred StockC Conversion	Director	CConversion	0 sh	—	—	0
2017-10-10	RYTMRHYTHM PHARMACEUTICALS, INC. · Series A Convertible Preferred StockC Conversion	Director	CConversion	0 sh	—	—	0
2017-10-10	RYTMRHYTHM PHARMACEUTICALS, INC.C Conversion	Director	CConversion	0 sh	—	—	0
2017-06-20	CTMXCytomX Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+14K sh	—	—	14,000
2017-03-27	CTMXCytomX Therapeutics, Inc.S Sale	Director	SSale	0 sh	—	—	0
2017-03-23	CTMXCytomX Therapeutics, Inc.S Sale	Director	SSale	0 sh	—	—	0
2016-11-07	CTMXCytomX Therapeutics, Inc.J Other	Director	JOther	0 sh	—	—	0
2016-06-10	CTMXCytomX Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+14K sh	—	—	14,000

Recent filings

Accepted (ET)
Sep 244
Exter Neil0001620014-25-000005
SEC(opens sec.gov)
Aug 194
Exter Neil0001415889-25-022301
SEC(opens sec.gov)
Jun 214
Exter Neil0000899243-22-023459
SEC(opens sec.gov)
Jun 214
Exter Neil0001567619-22-013195
SEC(opens sec.gov)
Jun 174
Exter Neil0001567619-22-013117
SEC(opens sec.gov)
Jun 104
Exter Neil0000899243-22-022011
SEC(opens sec.gov)
Jun 304
Exter Neil0001209191-21-044174
SEC(opens sec.gov)
Jun 244
Exter Neil0001567619-21-012593
SEC(opens sec.gov)
Jun 74
Exter Neil0000899243-21-022346
SEC(opens sec.gov)
May 274
Exter Neil0000899243-21-020884
SEC(opens sec.gov)
Feb 264
Exter Neil0000899243-21-008467
SEC(opens sec.gov)
Feb 194
Exter Neil0000899243-21-007436
SEC(opens sec.gov)

Companies

Address

C/O MAZE THERAPEUTICS, INC. 171 OYSTER POINT BOULEVARD, SUITE 300

SOUTH SAN FRANCISCO, CA, 94080